FR2637183A1 - Nouveaux inhibiteurs de la biosynthese du cholesterol et leur preparation - Google Patents

Nouveaux inhibiteurs de la biosynthese du cholesterol et leur preparation

Info

Publication number
FR2637183A1
FR2637183A1 FR8912856A FR8912856A FR2637183A1 FR 2637183 A1 FR2637183 A1 FR 2637183A1 FR 8912856 A FR8912856 A FR 8912856A FR 8912856 A FR8912856 A FR 8912856A FR 2637183 A1 FR2637183 A1 FR 2637183A1
Authority
FR
France
Prior art keywords
radical
optionally substituted
alkyl
symbols
hydrogen atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
FR8912856A
Other languages
English (en)
Inventor
Nigel Stephen Watson
Chuen Chan
Barry Clive Ross
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB888823192A external-priority patent/GB8823192D0/en
Priority claimed from GB888823191A external-priority patent/GB8823191D0/en
Priority claimed from GB898902847A external-priority patent/GB8902847D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of FR2637183A1 publication Critical patent/FR2637183A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Composés de la formule générale I : (CF DESSIN DANS BOPI) dans laquelle l'un des symboles R**1 et R**2 représente un radical alkyle en C1 -C6 , éventuellement substitué par de 1 à 3 atomes d'halogènes, cependant que l'autre de ces symboles représente un noyau phényle ou pyridyle ou un N-oxyde de celui-ci, éventuellement substitué par de 1 à 3 substituants choisis parmi les atomes d'halogènes et les radicaux hydroxyle, alkyle en C1 -C3 , alcoxy en C1 -C3 et trifluorométhyle; R**3 représente un radical phényle ou pyridyle ou un N-oxyde de celui-ci, éventuellement substitué par un ou plusieurs substituants choisis parmi les atomes d'halogènes et les radicaux hydroxyle, alkyle en C1 -C3 , alcoxy en C1 -C3 et trifluorométhyle, avec la condition que seul l'un des symboles R**1, R**2 et R**3 représente un noyau pyridyle éventuellement substitué, X représente -CH=CH- et Z représente un radical (CF DESSIN DANS BOPI) où R**4 représente un atome d'hydrogène, un radical protégeant la fonction carboxyle, ou un cation et R**5 représente un atome d'hydrogène ou un radical alkyle en C1 -C3 , et leurs solvates, et les sels d'addition d'acides des composés dans lesquels R**4 représente un atome d'hydrogène ou radical protégeant la fonction carboxyle.
FR8912856A 1988-10-03 1989-10-02 Nouveaux inhibiteurs de la biosynthese du cholesterol et leur preparation Pending FR2637183A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB888823192A GB8823192D0 (en) 1988-10-03 1988-10-03 Chemical compounds
GB888823191A GB8823191D0 (en) 1988-10-03 1988-10-03 Chemical compounds
GB898902847A GB8902847D0 (en) 1989-02-09 1989-02-09 Chemical compounds

Publications (1)

Publication Number Publication Date
FR2637183A1 true FR2637183A1 (fr) 1990-04-06

Family

ID=27264106

Family Applications (1)

Application Number Title Priority Date Filing Date
FR8912856A Pending FR2637183A1 (fr) 1988-10-03 1989-10-02 Nouveaux inhibiteurs de la biosynthese du cholesterol et leur preparation

Country Status (19)

Country Link
US (2) US5013749A (fr)
JP (1) JPH02188571A (fr)
KR (1) KR900006297A (fr)
AU (1) AU628862B2 (fr)
BE (1) BE1003007A3 (fr)
CH (1) CH680442A5 (fr)
DE (1) DE3932887A1 (fr)
DK (1) DK483689A (fr)
ES (1) ES2019163A6 (fr)
FI (1) FI894648A (fr)
FR (1) FR2637183A1 (fr)
GB (1) GB2223224B (fr)
GR (1) GR890100634A (fr)
IT (1) IT1237470B (fr)
LU (1) LU87600A1 (fr)
NL (1) NL8902441A (fr)
NO (1) NO893909L (fr)
PT (1) PT91878B (fr)
SE (1) SE8903226L (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3913725A1 (de) * 1989-04-26 1990-10-31 Basf Ag 1-halogenvinyl-azole und diese enthaltende fungizide und wachstumsregulatoren
CA2027179A1 (fr) * 1989-10-10 1991-04-11 Barry C. Ross Composes chimiques
SK4112003A3 (en) * 2000-10-12 2004-01-08 Nissan Chemical Ind Ltd Preventives and remedies for complications of diabetes
MXPA03009850A (es) * 2001-04-27 2004-02-12 Bristol Myers Squibb Co Inhibidores de bisarilimidazolil de hidrolasa de amida del acido graso.
MXPA06011657A (es) * 2004-04-16 2007-04-23 Warner Lambert Co Nuevos imidazoles.
US7199126B2 (en) * 2004-04-29 2007-04-03 Pharmix Corporation Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
EP1755607A2 (fr) * 2004-04-29 2007-02-28 Pharmix Corporation Compositions et traitements pour l'inhibition de kinase et/ou de hmg-coa reductase
US20050282883A1 (en) * 2004-04-29 2005-12-22 John Griffin Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US7163945B2 (en) * 2004-04-29 2007-01-16 Pharmix Corp. Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US20060084695A1 (en) * 2004-04-29 2006-04-20 John Griffin Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US20050272770A1 (en) * 2004-04-29 2005-12-08 John Griffin Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US7183285B2 (en) * 2004-04-29 2007-02-27 Pharmix Corp. Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US20060111436A1 (en) * 2004-11-23 2006-05-25 John Griffin Compositions and treatments for modulating kinase and/or HMG-CoA reductase
US8372877B2 (en) 2010-04-16 2013-02-12 Cumberland Pharmaceuticals Stabilized statin formulations
EP2626069A4 (fr) 2010-10-06 2014-03-19 Univ Tokyo Médicament destiné à la prévention et au traitement d'un lymph dème

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986007054A1 (fr) * 1985-05-22 1986-12-04 Sandoz Ag Analogues d'imidazole de mevalonolactone et leurs derives
US4647576A (en) * 1984-09-24 1987-03-03 Warner-Lambert Company Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
EP0221025A1 (fr) * 1985-10-25 1987-05-06 Sandoz Ag Analogues hétérocycliques de la mévalonolactone et dérivés de ceux-ci, leur procédé de préparation et leur application comme médicaments
EP0244364A2 (fr) * 1986-04-30 1987-11-04 Sandoz Ag Préparation de composés oléfiniques
EP0324347A2 (fr) * 1988-01-09 1989-07-19 Hoechst Aktiengesellschaft Acides 3,5-dihydroxycarboxyliques et leurs dérivés, procédé pour leur préparation, leur utilisation comme médicament, compositions pharmaceutiques et intermédiaires
EP0334014A2 (fr) * 1988-02-25 1989-09-27 Bayer Ag Imidazolinones et imidazolethiones substituées

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) * 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647576A (en) * 1984-09-24 1987-03-03 Warner-Lambert Company Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
WO1986007054A1 (fr) * 1985-05-22 1986-12-04 Sandoz Ag Analogues d'imidazole de mevalonolactone et leurs derives
EP0221025A1 (fr) * 1985-10-25 1987-05-06 Sandoz Ag Analogues hétérocycliques de la mévalonolactone et dérivés de ceux-ci, leur procédé de préparation et leur application comme médicaments
EP0244364A2 (fr) * 1986-04-30 1987-11-04 Sandoz Ag Préparation de composés oléfiniques
EP0324347A2 (fr) * 1988-01-09 1989-07-19 Hoechst Aktiengesellschaft Acides 3,5-dihydroxycarboxyliques et leurs dérivés, procédé pour leur préparation, leur utilisation comme médicament, compositions pharmaceutiques et intermédiaires
EP0334014A2 (fr) * 1988-02-25 1989-09-27 Bayer Ag Imidazolinones et imidazolethiones substituées

Also Published As

Publication number Publication date
SE8903226L (sv) 1990-04-04
DK483689A (da) 1990-04-04
FI894648A0 (fi) 1989-10-02
IT8948424A0 (it) 1989-10-02
PT91878B (pt) 1995-05-31
CH680442A5 (fr) 1992-08-31
IT1237470B (it) 1993-06-07
LU87600A1 (fr) 1990-05-15
NO893909L (no) 1990-04-04
PT91878A (pt) 1990-04-30
NL8902441A (nl) 1990-05-01
AU4243189A (en) 1990-04-05
GB8922212D0 (en) 1989-11-15
GB2223224A (en) 1990-04-04
AU628862B2 (en) 1992-09-24
ES2019163A6 (es) 1991-06-01
GB2223224B (en) 1992-01-08
DK483689D0 (da) 1989-10-02
KR900006297A (ko) 1990-05-07
GR890100634A (el) 1990-11-29
JPH02188571A (ja) 1990-07-24
FI894648A (fi) 1990-04-04
US5013749A (en) 1991-05-07
NO893909D0 (no) 1989-10-02
US5120848A (en) 1992-06-09
SE8903226D0 (sv) 1989-10-02
BE1003007A3 (fr) 1991-10-22
DE3932887A1 (de) 1990-04-05

Similar Documents

Publication Publication Date Title
FR2637183A1 (fr) Nouveaux inhibiteurs de la biosynthese du cholesterol et leur preparation
BE1002167A5 (fr) Derives de l'adenosine.
YU47122B (sh) 5-deoksi-5-fluorocitidinski derivati
FI914187A (fi) Menetelmä valmistaa kaavan /I/ mukaista 1-metyylikarbapeneemijohdosta
FI904915A0 (fi) Kinolinderivat, deras framstaellning och anvaendning.
MA31674B1 (fr) Dérivés de 7 -alkynyl-1,8-naphthyridones, leur préparation et leur application en thérapeutique
TNSN07114A1 (fr) Derives de pyridine, leur preparation, leur application en therapeutique
BE904641A (fr) 5-pyrimidine-carboxamides et traitement de la leucemie et des tumeurs avec ces derniers.
FR2452483A1 (fr) Derives d'alcenylphenylmaleimides, leurs dimeres lineaires et leur procede de preparation
BE904587A (fr) Intermediaires intervenant dans la production d'epipodophyllotoxine et composes apparentes : procedes de preparation et emploi.
FR2412553A1 (fr) Nouveaux antibiotiques de cephalosporine a large spectre
EP0262053A3 (fr) Nouveaux dérivés d'amino-acides, leur procédé de préparation et compositions pharmaceutiques les contenant
ES2038166T3 (es) Procedimiento para preparar un derivado de indenotiazol.
FR2355850A1 (fr) Composes organiques de l'etain tetrasubstitues
BE902147A (fr) Pesticides.
FR2413372A1 (fr) 2-(amino substitue)- n-(phenyl 3-substitue)-2-imidazolin-1-carbothioamides insecticides
DE69905695D1 (de) Benzo[b]pyranderivate verwendbar als äusserlich anzuwendende hautbehandlungsmittel
BE1003280A3 (fr) Derives oxo-isoindoliniques optiquement actifs.
DK0410953T3 (da) Piperidinforbindelser
BE902015A (fr) Nouvelles 13,14,19,19,20-hexadehydro-carboprostacyclines et procede de preparation.
BE902014A (fr) Nouvelles 13,14,19,20-tetradehydro-carboprostacyclines et procede de preparation.
FR2592044A1 (fr) Derives de 4-hydroxycoumarine
BE902710A (fr) Procede stereospecifique pour la preparation d'azetidinones.
EP0591030A3 (fr) 1-Hétéroaryl-azétidines et -pyrrolidines comme 5-HT3 agonistes
GB2004885A (en) Indolopyrones